Geopolitical tension in the Strait of Hormuz has quickly shifted attention back to energy security, shipping routes and the companies tied to global oil flows. With the IMO pausing its Gulf evacuation plan after an Evergreen container ship attack and Iran reinforcing control over key sea lanes, investors are weighing how higher risk, disrupted traffic and rising insurance costs may affect valuations. This article looks at 3 stocks from an Energy Sector Stocks screener that are closely exposed to this news and may help you assess where the market is pricing in opportunity, resilience or added volatility.

Brady (BRC)

Overview: Brady is a Milwaukee based industrial company that makes identification and safety products such as signs, labels, printers, spill control gear and lockout/tagout devices that help factories, energy facilities, hospitals and other workplaces keep people, equipment and assets clearly marked and compliant with regulations.

Operations: Brady generates about US$1.1b of revenue from the Americas & Asia segment and around US$550.6m from Europe & Australia.

Market Cap: US$4.1b

Brady gives investors exposure to safety, compliance and traceability spending that tends to sit behind the headlines of oil price swings, yet touches energy producers, data centers and healthcare systems alike. The company is leaning into higher margin automation and track and trace solutions, backed by acquisitions such as Honeywell PSS and solid R&D, while the new CEO is financially aligned after recently increasing his shareholding. At the same time, higher tariffs, a heavier debt load to fund deals and reliance on external borrowing keep execution risk real. For investors who want to understand whether that balance of growth and balance sheet risk still looks attractive, the full Brady story matters.

Brady’s shift toward higher margin automation and track and trace solutions could be reshaping its earnings quality. However, the debt funded dealmaking raises questions that a Brady financial health report only fully answers.

Dana (DAN)

Overview: Dana is a Maumee, Ohio based company that supplies axles, driveshafts, transmissions, electric drive systems and thermal and sealing products that help move and manage power in light and heavy vehicles, including trucks and off highway equipment used around oil and gas operations.

Operations: Dana generates about US$5.4b of revenue from its Light Vehicle segment and around US$2.4b from Commercial Vehicle, partly offset by US$194m of inter segment eliminations.

Market Cap: US$3.1b

Dana sits at an interesting crossroads for investors watching Gulf tensions and energy supply routes, because its driveline and thermal products feed into heavy trucks and off highway vehicles that support oil, gas and infrastructure activity. At the same time, the company is also pushing harder into electrified powertrains. The stock currently trades on a low P/S multiple, even as analysts expect strong earnings growth, margin improvement and high future ROE, with the planned Eaton Mobility merger and targeted cost savings adding another layer of potential upside. Against that, Dana is still loss making, relies heavily on external borrowing and faces customer concentration and execution risk on large new programs, which makes deeper due diligence especially important around this story.

Dana’s low P/S and push into electrified powertrains suggest that the market might be missing something about this turnaround story, and the 4 key rewards and 1 important warning sign could reveal the one pressure point that really matters.

Belite Bio (BLTE)

Overview: Belite Bio is a San Diego based clinical stage biopharmaceutical company developing oral drugs for eye and liver diseases, led by Tinlarebant, which is in a phase 3 trial for Stargardt disease type 1 and geographic atrophy, and backed by an earlier stage RBP4 therapy for conditions such as fatty liver disease, type 2 diabetes and gout.

Market Cap: US$5.9b

Belite Bio is drawing attention because it sits at the point where a potential first approval for Tinlarebant in Stargardt disease could turn a pre revenue biotech with a US$77.6 million annual loss into a company preparing for its first commercial launch. The rolling NDA submission under multiple FDA designations and a large cash and securities position of US$772.6 million give it room to fund R&D and build a commercial footprint ahead of any green light. At the same time, investors need to weigh real risks around trial outcomes, pricing pushback in rare disease and possible future dilution if timelines slip. What those moving pieces might mean for future earnings, valuation and downside protection is where the story gets more interesting for long term holders.

Belite Bio’s potential shift from a US$77.6 million annual loss to its first commercial revenue is where the story really accelerates, and the analyst forecasts for Belite Bio hint at one underappreciated twist investors often miss

The 3 stocks covered here are just a starting point. The full screener surfaces 41 more energy companies whose business models and risk profiles could matter just as much for your portfolio as headlines from the Strait of Hormuz. To identify and analyze those additional opportunities in detail, use the Energy Sector Stocks (Oil & Gas Producers and Oil Services) screener to filter for the exact catalysts, financial traits and narratives that match your highest conviction ideas.

Take Control of Your Investment Journey

If Belite Bio or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before The Crowd Moves?

Fresh stock ideas can move from quiet to crowded fast, as momentum builds, breakouts form and laggards get caught dropping. Scan these under the radar picks now to review them early.

• Target steady income while others chase headlines by reviewing 1 dividend fortresses built to help you focus on payouts that may keep working even when sentiment cools.
• Spot early movers in AI before the story goes mainstream by scanning 61 profitable AI stocks that aren't just burning cash where cash generation, not hype, sits at the center of the list.
• Review potential infrastructure-related ideas by checking 34 power grid technology and infrastructure stocks featuring companies tied to grid upgrades and electrification while that theme is still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.